Pyxis Oncology Income Statement (2024-2025) | PYXS

Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 16.15M2.82M
Gross Profit 15.67M2.82M
Operating items
Amortization - Intangibles 1.29M1.64M1.65M1.53M1.16M0.90M0.53M
Research & Development 13.03M13.95M17.74M14.02M17.04M17.13M17.81M
Selling, General & Administrative 8.25M6.08M6.01M5.08M5.87M5.44M5.65M
Other Operating Expenses 0.47M20.96M
Operating Expenses 21.75M20.03M23.75M40.07M22.91M22.57M23.46M
Operating Income -5.61M-20.03M-23.75M-40.07M-22.91M-19.75M-23.46M
EBIT -5.61M-20.03M-23.75M-40.07M-22.91M-19.75M-23.46M
Non-operating items
Non Operating Investment Income -0.12M-0.04M0.45M-0.18M-0.12M-0.05M0.07M
Interest & Investment Income 1.60M2.02M1.85M1.62M1.24M1.00M0.80M
Non Operating Income 2.35M2.73M2.55M2.33M1.76M1.68M1.46M
Net income details
EBT -4.00M-17.30M-21.20M-37.73M-21.67M-18.07M-22.00M
Tax Provisions -2.16M0.28M
Profit After Tax -3.30M-17.30M-21.20M-35.53M-21.20M-18.35M-22.00M
Income from Continuing Operations -4.00M-17.30M-21.20M-35.57M-21.67M-18.35M-22.00M
Consolidated Net Income -4.00M-17.30M-21.20M-35.57M-21.67M-18.35M-22.00M
Income towards Parent Company -4.00M-17.30M-21.20M-35.57M-21.67M-18.35M-22.00M
Net Income towards Common Stockholders -4.00M-17.30M-21.20M-35.57M-21.67M-18.35M-22.00M
Additional items
EPS (Basic) -0.06-0.29-0.35-0.61-0.35-0.30-0.35
EPS (Weighted Average and Diluted) -0.06-0.29-0.35-0.61-0.35-0.30-0.35
Shares Outstanding (Weighted Average) 51.29M60.50M60.72M58.45M61.05M61.92M62.56M
Shares Outstanding (Diluted Average) 51.29M60.50M60.72M58.45M61.05M61.92M62.56M
EBITDA -3.38M-17.34M-20.75M-35.75M-21.28M-18.41M-21.93M
Shares Outstanding 58.80M58.91M59.45M59.97M61.63M62.02M62.15M
Tax Rate 5.73-1.57